MAPT and Parkinson disease: We did not detect meaningful differences in CSF amyloid-beta1–42, total tau and phospho-tau181 in the CSFasynSAA− and CSFasynSAA+ groups, despite applying cut-offs26 that may be more sensitive to abnormalities in the Parkinson’s disease population27 (observed differences in total tau and phospho-tau were small in magnitude and likely explained by age).